SUPN logo

SUPN
Supernus Pharmaceuticals Inc

2,372
Mkt Cap
$2.8B
Volume
526,839.00
52W High
$59.68
52W Low
$30.83
PE Ratio
-94.18
SUPN Fundamentals
Price
$48.21
Prev Close
$49.38
Open
$49.38
50D MA
$49.91
Beta
0.58
Avg. Volume
538,082.45
EPS (Annual)
-$0.6829
P/B
2.60
Rev/Employee
$924,102.83
$2,537.93
Loading...
Loading...
News
all
press releases
What to Know About This Fund's Sale of a Pharma Stock Up 56% in a Year
Key PointsQuantedge Capital exited 89,600 shares of Supernus Pharmaceuticals in the first quarter, with an estimated trade size of $4.56 million based on quarterly average prices...
News Placeholder
More News
News Placeholder
Supernus Pharmaceuticals Q1 Earnings Call Highlights
Supernus Pharmaceuticals (NASDAQ:SUPN) reported first-quarter 2026 results that management said reflected "a strong start to the year," driven by growth across its key brands and collaboration-related revenue. Chief Executive Officer Jack Khattar highlighted a 56% year-over-year increase in combined...
News Placeholder
Supernus (SUPN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Supernus (SUPN) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
News Placeholder
Supernus Pharmaceuticals (SUPN) Beats Q1 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +110.71% and +10.22%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Quarterly Earnings Results
Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) issued its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter...
News Placeholder
Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 5.0% during the fourth quarter, according to the company in its most recent Form...
News Placeholder
Bausch Health (BHC) Lags Q1 Earnings Estimates
Bausch (BHC) delivered earnings and revenue surprises of -3.11% and +4.72%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Biogen Beats Q1 Earnings Estimates but Cuts 2026 EPS View on M&A Costs
Biogen beats Q1 earnings and revenue estimates, fueled by new drug growth, but cuts 2026 EPS outlook to reflect M&A costs.
News Placeholder
Supernus Pharmaceuticals (NASDAQ:SUPN) Rating Increased to Hold at Zacks Research
Zacks Research upgraded Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Monday...
News Placeholder
Supernus Pharmaceuticals (SUPN) to Release Quarterly Earnings on Tuesday
Supernus Pharmaceuticals (NASDAQ:SUPN) will be releasing its Q1 2026 earnings after the market closes on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-supernus-pharmaceuticals-inc-stock...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available